Barbara Gayle Duncan Halozyme Therapeutics, Inc. (HALO) insider trading activity

Barbara Gayle Duncan is of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 15,754 shares of HALO, which is worth approximately $758,240. The most recent transaction as insider was on Apr 25, 2024, when has been sold 6,501 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.8K

0% 3M change

70.26% 12M change

Total Value Held $758,240

Barbara Gayle Duncan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Apr 25 2024	BUY Grant, award, or other acquisition	-	6,501 Added 29.21%	15,754 Common Stock
May 05 2023	BUY Grant, award, or other acquisition	-	8,065 Added 46.57%	9,253 Common Stock
Feb 03 2023	BUY Grant, award, or other acquisition	-	1,188 Added 50.0%	1,188 Common Stock

Also insider at

IMMU

IMMUNOMEDICS INC

Director

AVIR

Atea Pharmaceuticals, Inc. Healthcare

FUSN

Fusion Pharmaceuticals Inc. Healthcare

OVID

Ovid Therapeutics Inc. Healthcare

JNCE

Jounce Therapeutics, Inc. Healthcare

Director

ADAP

Adaptimmune Therapeutics PLC Healthcare

Director

BGD